Review of Experience in Clinical Trials of Specific Active Tumor-Associated Antigen Immunotherapy of Lung Cancer

  • A. Hollinshead
  • H. Takita
  • T. Stewart


The preparation of tumor-associated antigens (TAA) has been described in detail (Hollinshead 1978, 1980; Hollinshead et al. 1981, 1979, 1987, 1988, 1980; Stewart et al. 1976, 1986; Takita et al. 1985). Two categories of TAA are prepared for usage in immunotherapy (ITx) and clinical and laboratory evaluations: pure TAA, in which membranes are separated from carefully characterized tumor cells, the membranes are subjected to gentle, low frequency sonica-tion procedures, and the solubilized proteins are separated into active components, according to size, charge, affinity. After identification, characterization, and preclinical testing, selected components are used for therapy; and ultra-pure TAA, in which the above preparations are subjected to further purification, especially by isotachophoresis, and alternately by monoclonal antibody-affinity chromatography. These preparations are used in particular for characterization, initial clinical studies, for hybridomas, and epitope preparations. Both forms of TAA are biologically active and immunogenic. Some of the methods used throughout for identification and characterization are: 1. Stepwise, gradient polyacrylamide gel electrophoresis (PAGE) and SDS-PAGE, using well-defined control preparations of known MW determination; migration and densitometry profiles and other chemical studies are performed for usage in comparison with libraries of previously studied specimens. These standard studies are optionally followed by studies with 2D slab gel or blotting techniques.


Lung Cancer Standard Study Immunotherapy Trial Specific Active Immunotherapy Early Lung Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Hollinshead A (1978) Active-specific immunotherapy. In: Univ Texas Sys Cancer Ctr (ed staff) Immunotherpay of Human Cancer. Raven, New York, pp 213–233Google Scholar
  2. Hollinshead A (1980) Cancer Detec Prev 3:419–448PubMedGoogle Scholar
  3. Hollinshead A, Stewart T (1981) Yale J Biol Med 54:367–379PubMedGoogle Scholar
  4. Hollinshead A, Stewart T, Takita H (1979) Tumor-associated antigens: their usefulness as biological drugs. In: F. Muggia, S. Rozencweig (eds) Lung cancer progress in therapeutic research. Raven, New York pp 501–520Google Scholar
  5. Hollinshead A, Stewart T, Yonemoto R, Arien M, Takita H (1980) Immunotherapy of advanced disease. In: R. Cripsin (ed) Tumor Progression. Elsevier, Amsterdam, pp 290–300Google Scholar
  6. Hollinshead A, Stewart T, Takita H et al. (1987) Cancer 60:1249–1262PubMedCrossRefGoogle Scholar
  7. Hollinshead A, Takita H, Stewart T, Raman S (1988) Cancer 62:1662–1671PubMedCrossRefGoogle Scholar
  8. Stewart T, Hollinshead A, Harris J (1976) Ann NY Acad sci 277:436–466PubMedCrossRefGoogle Scholar
  9. Stewart T, Shelley W, Willan A, Hollinshead A (1986) An evaluation of the role of tumor-specific antigens. In: Univ Texas Sys Cancer Ctr (ed staff) Lung cancer: current status and prospects for the future. Univ Texas Press, Austin, pp 351–374Google Scholar
  10. Takita H, Hollinshead A, Hart Jr T et al (1985) Cancer Immunol Immunother 20:231–235PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1989

Authors and Affiliations

  • A. Hollinshead
    • 1
  • H. Takita
    • 2
  • T. Stewart
    • 3
  1. 1.Division of Hematology/Oncology, Department of MedicineThe George Washington University Medical CenterUSA
  2. 2.Division of SurgeryThe Roswell Park Memorial Cancer CenterBuffaloUSA
  3. 3.Department of MedicineThe Ottawa University Medical CenterOttawaCanada

Personalised recommendations